MoMa Signature During Granulomatosis

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

Sarcoidosis is a systemic inflammatory disease characterized by unspecific granuloma formation. Our hypothesis is that granuloma formation and maintenance mainly relies on the overactivation of monocytes (Mo) and macrophages (Ma). To this end, the study aims (i) to define MoMa systemic signature in sarcoidosis, (ii) to characterize this signature in situ on tissue samples, and (iii) to identify causative factors that participate to the MoMa chronic overactivation. Thus, a cohort of sarcoidosis patients will be compared with tuberculosis patients. The MoMa systemic signature will be defined on whole blood (TruCulture model) and then in situ through different methods (multi-parameter spectral flow cytometry, RNA-seq, Luminex, imaging mass cytometry). The epigenome of monocytes will be studied thanks to CUT\&Tag. The MoMa systemic signature will be defined ex vivo at different time points during the course of the disease with phenotypic, transcriptomic, cytokine and functional approaches. The previously identified signature will be studied in situ and completed by the characterization of granuloma architecture and microenvironmental interactions, which could be modulated by epigenetic modifications. Hence, the epigenome of monocytes will be analyzed in two groups (sarcoidosis and tuberculosis). These results would allow to better understand sarcoidosis physiopathology and, in fine, may raise new therapeutic strategies. Finally, the study could challenge the dogma on innate immunity/auto-inflammation versus adaptive immunity/auto-immunity/memory.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Male and female > 18 years old

Diagnosis of sarcoidosis and of tuberculosis

Affiliated to medical insurance

Disqualifiers

HIV infection

pregnant or breastfeeding woman

Patient under legal protection, guardianship or curators

Absence of signed consent" Secondary exclusion criteria Other causes of granulomatosis ultimately identified as sarcoidosis or tuberculosis

Trial population

Adult patients diagnosed with sarcoidosis or tuberculosis

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • blood sample

    Other intervention

    blood sample collection

Treatment groups

100 Participants
are divided into 2 treatment groups
Group A: Sarcoidosis1 intervention
Group B: Tuberculosis1 intervention

Trial outcomes

Primary outcomes

1

macrophage activation in sarcoidosis measured by epigenomic

performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood

Time frame
up to 12 months of follow-up.
2

monocyte activation in sarcoidosis measured by epigenomic

performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood

Time frame
up to 12 months of follow-up.
3

macrophage activation in sarcoidosis measured by spatial transcriptomics

performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood

Time frame
up to 12 months of follow-up.
4

monocyte activation in sarcoidosis measured by spatial transcriptomics

performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood

Time frame
up to 12 months of follow-up.

Secondary outcomes

1

monocyte activation in tuberculosis measured by epigenomic

Time frame
up to 12 months of follow-up.
2

Identification of a pathogen that triggers sarcoidosis development by metagenomic study

Time frame
Samples collected before treatment/at diagnosis
3

identification of epigenetic modifications of monocytes by CUT&Tag method

CUT\&Tag-sequencing, also known as cleavage under targets and tagmentation, is a method used to analyze protein interactions with DNA

Time frame
12 months of follow-up.
4

Identification of a diagnostic test to discriminate sarcoidosis and tuberculosis

measurement of IFNγ secretion by whole blood in response to stimulation by tuberculosis antigen

Time frame
Samples collected before treatment/at diagnosis

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.